Anzeige
Mehr »
Login
Samstag, 21.12.2024 Börsentäglich über 12.000 News von 679 internationalen Medien
Breaking News: Vorweihnachtlicher Kaufrausch an der Börse?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A402TW | ISIN: US88165K1016 | Ticker-Symbol: G28
Tradegate
20.12.24
16:56 Uhr
1,020 Euro
+0,070
+7,37 %
1-Jahres-Chart
TEVOGEN BIO HOLDINGS INC Chart 1 Jahr
5-Tage-Chart
TEVOGEN BIO HOLDINGS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,9150,99520.12.

Aktuelle News zur TEVOGEN BIO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrTevogen Bio (TVGN) Advances AI-Driven Immunotherapy with New Patent Filing1
DoTevogen Bio Inc: Tevogen Bio Strengthens Robust IP Portfolio With Filing of Predictive AI Patent, With the Goal to Establish a Blueprint to Unlock the Full Potential of T Cell Therapies and Accelerate AI Integration to Advance Its Bold Growth ...2
TEVOGEN BIO Aktie jetzt für 0€ handeln
05.12.Tevogen Bio Inc: Dr. Ryan Saadi Commends Individuals Who Dedicate Time to Public Service, and Congratulates Mayor Victor Sordillo on His Induction Into the NJ League of Municipalities Hall of Fame2
26.11.Tevogen Bio Inc: Tevogen Bio Prepares Organizational Readiness to Support Company's Growth Strategy2
21.11.Tevogen Bio Inc: Tevogen Bio CEO Reflects on Public Support, Reaffirms Preserving Shareholder Value Remains His Priority, and Reinforces Options Including a Potential Share Buyback to Support Company Value65WARREN, N.J., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically...
► Artikel lesen
19.11.Tevogen Bio Holdings reports Q3 results6
19.11.Tevogen Bio Inc: Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance Sheets, Efficient Business Model101Improved operating performance by reducing net loss by $52.5 million; reported net loss of $4.3 million and $56.8 million for the nine months ended September 30, for 2024 and 2023, respectively.Significantly...
► Artikel lesen
19.11.Tevogen Bio Holdings Inc. - 10-Q, Quarterly Report2
15.11.Tevogen Bio Holdings Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB1
14.11.Tevogen Bio Inc: Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials1
11.11.Tevogen Bio Partners with Microsoft Corporation (MSFT) to Leverage Advanced AI Tools for Biotech Research in Healthcare5
08.11.Tevogen Bio Inc: Tevogen Bio Nears Finalization of Agreement to Enhance R&D and Manufacturing Capabilities; $36 Million Line of Credit Available for Continued Operations75WARREN, N.J., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically...
► Artikel lesen
06.11.Tevogen Bio partners Microsoft for HPV treatment12
05.11.Tevogen Bio Inc: Tevogen Bio CEO Dr. Ryan Saadi Expresses Gratitude for Prestigious ROI-NJ Recognition, Highlighting Company's Novel Business Model as Key to Sustainable Success through Patient Affordability3
05.11.Tevogen Bio Inc: Tevogen Bio Leverages Microsoft Partnership to Deliver Machine Learning Based Target Identification to Address Human Papilloma Virus (HPV), Advancing TVGN 9203
04.11.Tevogen Bio Inc: Tevogen Bio Announces Appointment of Anthony Tarantino as Patient Advocate to Enhance Community Engagement and Patient Support2
31.10.Tevogen partners with Microsoft to speed up drug development8
31.10.Tevogen kooperiert mit Microsoft zur Beschleunigung der Medikamentenentwicklung9
31.10.Tevogen Bio Inc: Tevogen Bio Expands on Microsoft Partnership to Integrate Machine Learning and AI into Preclinical Processes, Accelerating Drug Development and Reducing Costs4
29.10.Tevogen Bio Inc: Tevogen Bio Reports Nasdaq Listing Compliance as CEO Reaffirms His Commitment in Bridging the Information Gap About the Company175Regained compliance without effecting a reverse stock splitTevogen Bio CEO reaffirms his commitment to preserve shareholder value WARREN, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen"...
► Artikel lesen
Seite:  Weiter >>
81 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1